Romiplostim: Una nueva oportunidad en PTI

• Autores: Chelo Jordán de Luna, Eva Romá Sánchez, Isidro Jarque Ramos, José Luis Poveda Andrés
• Localización: Atención Farmacéutica, ISSN 1139-7357, Vol. 13, Nº. 5, 2011, págs. 294-302
• Idioma: español
• Títulos paralelos:
  • Romiplostim: A new chance in ITP
• Texto completo no disponible (Saber más ...)
• Resumen

  • Romiplostim is the first megakaryopoiesis-stimulating agent marketed for the treatment of idiopathic thrombocytopenic purpura (ITP). Its action mechanism is the result of a new focus on the treatment for ITP directed at correcting deficient platelet production, versus the traditional immunological treatments. Romiplostim's safety and efficacy have been evaluated in two stage-Ill clinical trials and a later extension study. Its adverse reaction profile ranges from the most frequent reactions, mild-level ones like headaches or fatigue, to severe adverse events in a lower percentage like the increase of medullary reticulin or thromboembolic events. In this work, we analyzed the state of the current knowledge about this drug and described our experience. A long-term follow-up of romiplostim shall be required for those ITP patients where its efficacy has been proven, as well as its possible application for other pathologies related to thrombocytopenia